Literature DB >> 29499272

Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Landon M Klein1, Nicholas V Cozzi2, Paul F Daley3, Simon D Brandt4, Adam L Halberstadt5.   

Abstract

Substantial effort has been devoted toward understanding the psychopharmacological effects of tryptamine hallucinogens, which are thought to be mediated by activation of 5-HT2A and 5-HT1A receptors. Recently, several psychoactive tryptamines based on the N,N-diallyltryptamine (DALT) scaffold have been encountered as recreational drugs. Despite the apparent widespread use of DALT derivatives in humans, little is known about their pharmacological properties. We compared the binding affinities of DALT and its 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 5-methoxy-, 5-methoxy-2-methyl-, 5-fluoro-, 5-fluoro-2-methyl-, 5-bromo-, and 7-ethyl-derivatives at 45 receptor and transporter binding sites. Additionally, studies in C57BL/6 J mice examined whether these substances induce the head twitch response (HTR), a 5-HT2A receptor-mediated response that is widely used as a behavioral proxy for hallucinogen effects in humans. Most of the test drugs bound to serotonin receptors, σ sites, α2-adrenoceptors, dopaminergic D3 receptors, histaminergic H1 receptors, and the serotonin transporter. DALT and several of the ring-substituted derivatives were active in the HTR assay with the following rank order of potency: 4-acetoxy-DALT > 5-fluoro-DALT > 5-methoxy-DALT > 4-hydroxy-DALT > DALT > 5-bromo-DALT. 2-Phenyl-DALT, 5-methoxy-2-methyl-DALT, 5-fluoro-2-methyl-DALT, and 7-ethyl-DALT did not induce the HTR. HTR potency was not correlated with either 5-HT1A or 5-HT2A receptor binding affinity, but a multiple regression analysis indicated that 5-HT2A and 5-HT1A receptors make positive and negative contributions, respectively, to HTR potency (R2 = 0.8729). In addition to supporting the established role of 5-HT2A receptors in the HTR, these findings are consistent with evidence that 5-HT1A activation by tryptamine hallucinogens buffers their effects on HTR. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'. Published by Elsevier Ltd.

Entities:  

Keywords:  4-AcO-DALT; 4-Acetoxy-N,N-diallyltryptamine; 4-Hydroxy-N,N-diallyltryptamine; 5-MeO-DALT; 5-Methoxy-N,N-diallyltryptamine; Hallucinogen; Head twitch; Mice; Psychedelic

Mesh:

Substances:

Year:  2018        PMID: 29499272      PMCID: PMC6230509          DOI: 10.1016/j.neuropharm.2018.02.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  69 in total

1.  Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology.

Authors:  H T Kao; N Adham; M A Olsen; R L Weinshank; T A Branchek; P R Hartig
Journal:  FEBS Lett       Date:  1992-08-03       Impact factor: 4.124

2.  Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats.

Authors:  K Krebs-Thomson; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

3.  The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.

Authors:  Theresa M Carbonaro; Amy J Eshleman; Michael J Forster; Kejun Cheng; Kenner C Rice; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2014-07-03       Impact factor: 4.530

4.  Online test purchased new psychoactive substances in 5 different European countries: A snapshot study of chemical composition and price.

Authors:  Tibor Markus Brunt; Amanda Marie Atkinson; Thomas Nefau; Magali Martinez; Emmanuel Lahaie; Artur Malzcewski; Martin Pazitny; Vendula Belackova; Simon D Brandt
Journal:  Int J Drug Policy       Date:  2017-05-01

5.  Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.

Authors:  Julian A Michely; Andreas G Helfer; Simon D Brandt; Markus R Meyer; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2015-08-22       Impact factor: 4.142

Review 6.  The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review.

Authors:  John M Corkery; Emma Durkin; Simon Elliott; Fabrizio Schifano; A Hamid Ghodse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-06-07       Impact factor: 5.067

7.  Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.

Authors:  W E Fantegrossi; J Simoneau; M S Cohen; S M Zimmerman; C M Henson; K C Rice; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2010-09-21       Impact factor: 4.030

8.  Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice.

Authors:  Mireille Basselin; Meredith A Fox; Lisa Chang; Jane M Bell; Dede Greenstein; Mei Chen; Dennis L Murphy; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

9.  Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD.

Authors:  R Young; J A Rosecrans; R A Glennon
Journal:  Life Sci       Date:  1982-06-14       Impact factor: 5.037

10.  Studies on several 7-substituted N,N-dimethyltryptamines.

Authors:  R A Glennon; E Schubert; J M Jacyno; J A Rosecrans
Journal:  J Med Chem       Date:  1980-11       Impact factor: 7.446

View more
  13 in total

1.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

2.  Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Geraldine Dowling; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2019-06-18       Impact factor: 3.345

3.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.

Authors:  Adam L Halberstadt; Muhammad Chatha; Stephen J Chapman; Simon D Brandt
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

4.  Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).

Authors:  Adam L Halberstadt; Landon M Klein; Muhammad Chatha; Laura B Valenzuela; Alexander Stratford; Jason Wallach; David E Nichols; Simon D Brandt
Journal:  Psychopharmacology (Berl)       Date:  2018-10-08       Impact factor: 4.530

5.  Investigation of the Structure-Activity Relationships of Psilocybin Analogues.

Authors:  Adam K Klein; Muhammad Chatha; Lauren J Laskowski; Emilie I Anderson; Simon D Brandt; Stephen J Chapman; John D McCorvy; Adam L Halberstadt
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-14

6.  Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.

Authors:  Janis Fricke; Alexander M Sherwood; Adam L Halberstadt; Robert B Kargbo; Dirk Hoffmeister
Journal:  J Nat Prod       Date:  2021-03-05       Impact factor: 4.803

7.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

8.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

10.  Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.

Authors:  Monika Herian; Adam Wojtas; Małgorzata Katarzyna Sobocińska; Mateusz Skawski; Alejandro González-Marín; Krystyna Gołembiowska
Journal:  Pharmacol Rep       Date:  2020-11-10       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.